Jim Tananbaum is the founder of Foresite Capital. The idea of starting the company emanated from his experience of more than 25 years where he served as a healthcare investment strategist and entrepreneur. To Jim, Foresite means to harness and understand healthcare’s future. He was inspired to incorporate Foresite after recognizing that innovative healthcare solutions and products always require huge capital and time than most financiers and entrepreneurs appreciate. To this end, Jim was optimistic that Foresite could play an important role of providing emerging leaders with capital, information, and networks to enable them succeed with their respective undertakings.
Foresite’s portfolio has expanded to 77 different healthcare companies in medical services, biopharmaceuticals, genomic sequencing, and diagnostics. Jim spends most of his working days with other members of his team in meetings and on calls. They focus on providing healthcare leaders with a platform of making scientific discoveries that can make a significant impact on healthcare.
Jim Tananbaum incorporated Foresite Capital in 2011 as a dedicated healthcare equity company that specializes in identifying start-up healthcare leaders and helping them to grow. Before establishing Foresite Capital, Jim had co-founded two healthcare investment companies and two major biopharmaceutical firms. One of the firms, GelTex Pharmaceuticals, made a significant milestone when it brought two drugs to the market for not more than $80 million. You can visit his About.me page.
About Jim Tananbaum
Jim’s investment experience includes serving as Prospect Partners II and III’s founding partner. Earlier in his career, he played a pivotal role in establishing the health services investment at Sierra Ventures where he was also a partner. Additionally, Jim has led several investments, including Amerigroup, Healtheon, Amira Pharmaceuticals, and Jazz Pharmaceuticals. His vision for Foresite Capital is bringing together all components of his career to create a new investment platform.
Jim earned his MD and MBA from the revered Harvard University. He holds a master’s of science degree from the world-renowned Massachusetts Institute of Technology (MIT). He is also an alumnus of the prestigious Yale University. His passion is to work closely with leading academicians and entrepreneurs to enhance growth in the healthcare industry and other fields. Jim has maintained his leading position on the Midas List for three consecutive years. This success has been brought about by several healthcare investments, including Intarcia Therapeutics, diabetes treatment, and Juno Therapeutics that entered the market in December 2014 as the leading biotech IPO in that year.
See more: https://ideamensch.com/jim-tananbaum/